Needham Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $212

Benzinga · 05/11/2023 07:05
Needham analyst Ami Fadia maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $205 to $212.